key: cord-1018994-dpuc7ay6 authors: Selvarajan, Sandhiya; Anandaradje, Annuja; Shivabasappa, Santhosh; Melepurakkal Sadanandan, Deepthy; Nair, N. Sreekumaran; George, Melvin title: Efficacy of pharmacological interventions in COVID‐19: A network meta‐analysis date: 2022-04-13 journal: Br J Clin Pharmacol DOI: 10.1111/bcp.15338 sha: 95a8c3407ad8f3b707e19bf10c187530b7b029de doc_id: 1018994 cord_uid: dpuc7ay6 AIMS: To perform network meta‐analysis for a head‐to‐head comparison of various interventions used in coronavirus disease 2019 (COVID‐19) on mortality, clinical recovery, time to clinical improvement and the occurrence of serious adverse events. METHODS: Systematic search was performed using online databases with suitable MeSH terms including coronavirus, COVID‐19, randomized controlled trial, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, remdesivir, favipiravir, dexamethasone and interferon‐β. Data were independently extracted by 2 study investigators and analysed. RESULTS: Out of 1225 studies screened, 23 were included for qualitative and quantitative analysis. Among the drugs studied, dexamethasone reduces mortality by 10%, with a relative risk of 0.90 (95% confidence interval [0.82–0.97]) and increases clinical recovery by 6% (relative risk 1.06, 95% confidence interval [1.02–1.10]) compared to standard of care. Similarly, remdesivir administered for 10 days increased clinical recovery by 10%, reduced time to clinical improvement by 4 days and lowered the occurrence of serious adverse events by 27% as compared to standard of care. CONCLUSION: In comparison to standard of care, dexamethasone was found to increase clinical recovery and lower mortality; remdesivir was significantly associated with a lower risk of mortality as compared to tocilizumab and higher clinical recovery and shorter time to clinical improvement as compared to hydroxychloroquine and tocilizumab; remdesivir followed by tocilizumab were found to have lesser occurrence of serious adverse events in patients with moderate to severe COVID‐19. In the earlier days of pandemic, HCQ, an antimalarial drug used widely in rheumatoid arthritis was proposed to be useful on the basis of in vitro evidence. 2 Nevertheless there have been conflicting reports about the effectiveness of HCQ with earlier reports favouring the utility of this medication in treating COVID-19. 3 Subsequently remdesivir was approved by the US Food and Drug Administration (FDA) for the treatment of severe COVID-19 infection on the basis of an improvement in the time to recovery following hospitalization. 4 However the drug was not found to be effective in reducing mortality as per the results of the World Health Organization (WHO) Solidarity trial. 5 Although corticosteroids interfere with the body's ability to control viral replication, few studies have highlighted their benefits in reducing mortality in severe COVID-19 patients admitted in the intensive care unit. 6 Additionally, tocilizumab, an interleukin-6 receptor antagonist has been shown to reduce the need for mechanical ventilation in This systematic review and NMA was carried out in accordance with the registered protocol in PROSPERO (CRD42021246551) and abides by the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) extension statement for reporting the systematic reviews incorporating NMA of health care interventions. The electronic bibliographic databases namely Cochrane Library All the randomized controlled studies in hospitalized COVID-19 patients of all age groups and sex with any pharmacological treatments were included. The exclusion criteria were studies done for prevention of COVID-19 in healthy populations, abstractonly articles, case reports, conference presentations, editorials, reviews, expert opinions, articles in a language other than English, etc. The outcomes assessed from the included studies were mortality, clinical recovery, time to clinical improvement and the occurrence of SAEs. For assessing the outcomes of mortality and clinical recovery, studies reporting death due to any cause by day 28 Titles and/or abstracts of studies were retrieved using the search strategy as mentioned. A standardized, pre-formatted form was used to extract data from the included studies for assessment of study quality and evidence synthesis. The data extracted include study setting, study population, study type, participant demographics and baseline characteristics, details of the intervention and control conditions, study methodology, randomization details, mortality, clinical recovery, time to clinical improvement, and the occurrence of SAEs. All the data were extracted either from text, tables, or figures of the published articles. Data from the figures and graphs were extracted using WebPlotDigitizer software (version 4.1, https://automeris.io/ WebPlotDigitizer/). Two of the review authors extracted the data independently, identified discrepancies and resolved them through discussion with a third author. The NMA includes only randomised controlled trials in which the risk of bias was assessed according to the standards laid down by the Cochrane handbook of meta-analysis. 9 The domains of bias assessment include: randomization sequence generation, treatment allocation concealment, blinding, completeness of outcome data, selective reporting and other possible sources of bias. Disagreements between the review authors over the risk of bias in particular studies were resolved by discussion, with the involvement of a third review author, whenever necessary. An NMA within a frequentist framework was carried out using netmeta package available in R software version 4.1.1. 10 In a frequentist approach, the netmeta package uses graph theory techniques to describe the relative treatment effects of several treatments. 11 Network plots were drawn for visualizing the network geometry of the available evidence using STATA version 15.1 (Stata Corp, TX, USA). 12 Both global and local inconsistencies were assessed. Node splitting was done to check for the local inconsistency. 13 The statistical heterogeneity was quantified and tested using the I 2 and generalized Cochrane Q statistic. A random-effect model was used if sufficient heterogeneity was detected (I 2 > 50%), otherwise a fixed effect model was used. Summary estimates were reported as relative risk (RR) along with 95% confidence interval (CI) for dichotomous outcomes like mortality, clinical recovery and SAEs whereas difference in means (MD) and corresponding 95% CI for the continuous outcome (time to clinical improvement). A P-value <.05 was considered statistically significant. Net-league plots were used to represent all pairwise summary estimates from NMA. Reference-based Forest plots were plotted to display the pooled effect estimates obtained from the comparisons of different treatments to the standard of care. The standard of care was considered as the reference. P-score, a frequentist equivalent of the surface under the cumulative ranking (SUCRA) value was estimated in order to rank the treatments. 14 P-score (range from 0 to 1) represents the mean extent of certainty that a treatment is superior to other treatments, averaged over all competing treatments. Treatment with the highest P-score (near to 1) was considered as superior when compared to other competing treatments. Comparison-adjusted funnel plots were constructed to assess the publication bias and the asymmetry of the funnel was tested using Egger's test. 15 A sensitivity analysis was carried out to assess the robustness of the findings by excluding those studies with a mild-moderate population. The relative treatment estimates were obtained for those studies comprising of only moderate to severe population and the results were compared with the overall analysis. After screening 1225 titles and abstracts, 23 randomized controlled trials (RCTs) met the eligibility criteria and were included in the NMA (Table 1) . 5, 6, Of the 23 studies included, 6 were double-blinded (23%) and the rest were open-label (77%). Most trials had reported outcomes at 28-30 days except for 3 studies that had reported outcomes at 14 days. Both global and local inconsistencies were assessed and no statistical inconsistency was detected across the studies. Network plots depicting the interventions have been drawn for each of the outcomes with the standard of care as the most common comparator ( Figure 2 ). Two of the included trials had evaluated treatment against active comparator i.e. remdesivir administered for 10 days (R10) with remdesivir administered for 5 days (R5). Hence, we have classified remdesivir administered for 10 days (R10) as a different treatment node from remdesivir administered for 5 days (R5). No statistical incoherence was detected with this approach. All the included trials reported mortality, and the network analysis Among the included studies, 14 Figure 3B ). The remaining treatment interventions showed no significant effect on clinical recovery compared to standard of care. Only 16 of the included trials had reported on the occurrence of SAEs. Remdesivir administered for 10 days was found to be associated with a lower occurrence of SAEs compared to standard care (RR-0.73, 95% CI [0.61-.87]) followed by tocilizumab (RR-0.76, 95% CI [0.64-0.91]; Figure 3D ). Net league table (Tables 2A-D) Sensitivity analysis with studies involving only moderate to severe cases, found that dexamethasone and remdesivir were significantly associated with lower risk of mortality as compared to standard of care and HCQ respectively (Table S2A) . Similarly in sensitivity analysis dexamethasone and remdesivir were found to be significantly associated with improved clinical recovery as compared to standard of care (Table S2B ). In addition, sensitivity analysis findings were similar to the overall analysis of remdesivir having a shorter duration for clinical improvement as compared to tocilizumab and with a lower occurrence of SAEs as compared to standard of care (Table S2C, D) . The P-score can be interpreted as the mean extent of certainty that a treatment is better than other treatments, averaged over all competing treatments. Remdesivir administered for 10 days followed by dexamethasone were found to have a higher probability of reducing mortality as compared to other treatments (Table 3) . Also, remdesivir given for 10 days was found to have a higher probability on improving clinical recovery as compared to other competing treatments included in the study. However, lopinavir/ritonavir combination had a 79% certainty of being ranked first with fewer SAEs, followed by dexamethasone and remdesivir given for 10 days. Risk of bias in the included studies as assessed by Cochrane tool for assessing risk of bias in randomized trials (RoB 2.0) is presented in Figure S1 . Overall, the risk of bias was rated as low in 7 RCTs, some concerns in 9 and high in the remaining RCTs. Comparison of adjusted funnel plots were made for the visual assessment of asymmetry ( Figure 4) Our NMA found that lopinavir and ritonavir combination, interferon β, tocilizumab and HCQ were not effective in reducing mortality in COVID-19 infection. These findings are similar to the results of living NMA. 40 Similarly, a meta-analysis done to evaluate the efficacy of HCQ from 11 RCTs, showed that HCQ does not have any effect on time to clinical improvement, or mortality in COVID-19 patients. 48 Similarly, in the RECOVERY trial, hospitalized patients with COVID-19 on HCQ did not show reduction in mortality at the end of 28 days compared to the standard care. 49 The present NMA found that drugs such as favipiravir, tocilizumab and HCQ were ineffective in improving clinical recovery. This is in concurrence to the study by Self The present study could not assess the efficacy of newer drugs as it was done in the earlier part of the COVID-19 pandemic. Besides mortality, other endpoints such as the need for mechanical ventilation/intubation were not assessed in our study due to the paucity of data. Further, the standard of care provided might have been different across the regions lacking uniformity. Nevertheless, during the initial part of the pandemic when these published studies were being conducted, there was no consensus on the standard of care prescribed across the globe. This NMA was done exclusively from RCTs to avoid various bias included in the observational studies and to generate high-quality evidence. The study included only hospitalized patients with moderate to severe COVID-19 to reduce heterogeneity. This NMA of 23 randomised controlled trials done in hospitalized patients with moderate to severe COVID-19, found that dexamethasone reduces mortality and improves clinical recovery at the end of 28 days in comparison to standard of care. Likewise, remdesivir was significantly associated with a lower risk of mortality as compared to tocilizumab and had higher clinical recovery and shorter time to clinical improvement as compared to HCQ and tocilizumab. In addition, remdesivir and tocilizumab were associated with a lower occurrence of SAEs as compared to standard of care. As the pandemic is continuing, and various newer drugs and vaccines are being introduced to curb the disease, there is a need for NMA at a regular intervals to appraise the efficacy of the drugs used in COVID-19. COVID-19) Dashboard In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline FDA Approves First Treatment for COVID-19 Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results Dexamethasone in Hospitalized Patients with Covid-19 Tocilizumab in patients with severe COVID-19: a retrospective cohort study Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia Assessing risk of bias in a randomized trial. Cochrane Handb Syst Rev Interv Version 62 Cochrane Train Network Meta-Analysis Network Meta-Analysis Using R: A Review of Currently Available Automated Packages Graphical tools for network meta-analysis in STATA Measuring inconsistency in meta-analyses Ranking treatments in frequentist network meta-analysis works without resampling methods Bias in metaanalysis detected by a simple, graphical test Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial Remdesivir for the Treatment of Covid-19 -Final Report Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19 Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis Drug treatments for covid-19: living systematic review and network meta-analysis Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project) An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials Update: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points Information on COVID-19 Treatment, Prevention and Research [Internet]. COVID-19 Treatment Guidelines IDSA Guidelines on the Treatment and Management of Patients with COVID-19 Clinical management: living guidance Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a metaanalysis of randomized controlled trials Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial How to cite this article Efficacy of pharmacological interventions in COVID-19: A network meta-analysis None.